A reality check for university spin offs and emerging raw material companies

University spin offs and early-stage raw material companies are often built on outstanding science. A novel molecule, a new extraction process, or a compelling performance profile can feel like the hardest part of innovation is already behind you. In practice, this is only the beginning.

After more than twenty years working in development and regulatory across Pharma, Cosmetics, and Chemical industries, including time in large ingredient suppliers such as Croda and later supporting university spin offs including one originating from UCL, one pattern appears repeatedly. Many technically excellent ingredients struggle to reach market adoption not because they fail scientifically, but because market readiness is misunderstood.

This article is not about a specific project. It is about the full circle of innovation that large chemical organisations internalise instinctively, but that smaller companies and spin offs often encounter too late.

A molecule is not a product

In academic and early commercial environments, innovation often begins with the molecule. Its structure, synthesis, purity and performance are explored thoroughly, often with impressive data. What is frequently missing is a clearly defined end use framed from the perspective of the formulator and the brand.

In consumer products, particularly cosmetics and home care, raw materials are not sold on novelty alone. They are adopted because they solve a problem within a formulation, fit into an existing development workflow, and support a credible marketing narrative.

An ingredient that performs exceptionally in isolation may still fail to gain traction if formulators cannot immediately understand where it fits, how it behaves in real formulations, and what story it enables downstream.

How large chemical companies think differently

One of the biggest differences between mature ingredient suppliers and early-stage companies is not technical capability, but sequence of thinking.

In large chemical organisations, development typically starts with a defined consumer or formulator need. This could be improved sensory feel, better stability under stress, regulatory friendly preservation support, or compatibility with trending claims. Only then is the chemistry designed to deliver that outcome.

From there, testing is not random or exploratory. It is targeted. Performance data, stability studies and safety assessments are selected specifically to support future positioning. Marketing language is not invented at the end. It is reverse engineered from evidence that has already been generated.

This creates a closed innovation loop where chemistry, testing, regulatory documentation and marketing are aligned from the beginning.

Spin offs frequently reverse this order, discovering market application, claims strategy and documentation requirements only after the molecule exists.

The hidden gap between performance and adoption

Raw material adoption in beauty and skincare is pragmatic. Formulators ask practical questions first:

• How easy is this ingredient to use?
• Does it drop into existing oil water or anhydrous systems?
• Is the supply chain reliable?
• Is the INCI name clear and recognised?
• What testing exists to support claims?

University spin offs often underestimate how much friction even small uncertainties create. If an ingredient requires unusual processing, lacks clear documentation, or forces reformulation of otherwise robust systems, adoption becomes slower regardless of performance.

Market readiness is not about how well an ingredient works under ideal conditions. It is about how easily it integrates into imperfect real-world formulations.

Testing without strategy creates weak narratives

Another common challenge arises from how testing is planned.

It is understandable that early-stage companies generate as much data as possible to demonstrate value. However, data without claims and positioning strategy rarely translates into strong marketing.

Testing should answer specific questions. Can this ingredient support moisturisation claims in realistic formulations. Does it improve stability under stress conditions that matter commercially. Does it enable reduction of other components for sustainability or cost control.

When test design is not linked to future use cases, marketing teams are forced to retrofit narratives to existing data. This often leads to over extended claims or underwhelming stories.

In contrast, testing designed as part of a broader development strategy becomes a tool for adoption rather than validation.

Regulatory and documentation are not administrative tasks

For many early companies, regulatory work and documentation are treated as hurdles encountered near launch. In reality, these elements shape development decisions much earlier.

A clear Technical Data Sheet, an understood INCI name pathway, and awareness of regional regulatory expectations influence how confidently formulators and procurement teams engage with a new ingredient.

Delaying these elements can stall commercial conversations even when science is strong. Market readiness includes being able to answer questions before they are asked, not scrambling to fill gaps later.

Consumer products demand translation, not just innovation

Beauty and homecare are translation driven industries. Scientific excellence must be translated into formulation value, regulatory clarity and marketing credibility.

This does not mean simplifying science. It means framing it in a way that makes immediate sense to the people who decide whether an ingredient enters a formulation brief.

Emerging raw material companies that succeed tend to invest early in understanding how their innovation will be perceived, questioned and challenged by formulators, safety assessors and marketers alike.

Market readiness as a mindset

The most important shift for spin offs and small ingredient companies is to view market readiness not as a final milestone, but as a mindset that informs every development decision.

It is asking early how this ingredient will be explained, used, tested, documented and defended. It is designing chemistry, testing and narratives as part of a single story rather than separate efforts.

When this mindset is adopted early, innovation moves faster, not slower. Rework is reduced. Conversations with customers become more concrete. Trust builds earlier.

Great science is essential, but it is not sufficient on its own. The ingredients that succeed in consumer products are those designed with the full circle in mind, from consumer need to molecule design to formulation use to market communication.

For university spin offs and emerging suppliers, bridging this gap earlier can be the difference between an ingredient that impresses on paper and one that is adopted in practice.

If you are developing a new cosmetic or personal care ingredient and want to understand how to move from promising science to true market readiness, Olalla Consulting works at the interface of formulation, processing and regulatory strategy.

Visit www.olallaconsulting.com to explore how we support ingredient developers and emerging companies in building adoption ready innovation.